DEKA has presented its latest innovative therapy, PelviTouch, for the treatment of erectile dysfunction, at the European Society for Sexual Medicine (ESSM) congress held in Vienna (February 2025). This technology was initially developed, with great success, for the treatment of urinary incontinence for both sexes, and it has now been optimized and specialized by DEKA’s research and development team to improve men’s intimate health, with effective treatments aimed specifically at erectile dysfunction, a field in which DEKA is an absolute pioneer.
The treatment PelviTouch uses a magnetic field generated by the “TOP FMS” technology (TOP Flat Magnetic Stimulation), which acts on the pelvic floor, a crucial area for the intimate health and sexual function. Thanks to the stimulation of peripheral nerves, the induced muscular contractions (lasting a couple of seconds) are greater compared to those obtainable voluntarily, strengthening pelvic muscles and improving erection. This treatment can also relax the muscles by bypassing voluntary muscle action, thereby reducing spasms and stiffness, which are often associated with conditions such as erectile dysfunction and urinary incontinence, as well as in all cases where pelvic muscle spasms occur.
Moreover, the therapy has proven to be useful also for urinary incontinence, in particular in the case of post-prostatectomy stress incontinence, thanks to the strengthening of pelvic muscles. PelviTouch has also a positive effect on the detrusor muscle, thereby contributing to reduce urination frequency and strong urination urge.
In conclusion PelviTouch normalizes the pelvic floor and “optimizes the erection” entering the market as a non-invasive, safe and highly effective solution for the treatment of male intimate ailments, combining advanced medical technologies with the wellbeing and satisfaction of the patient.
